

| index | context prefix/suffix |
|-------|--|
| 1 | During moments of fear or anxiety. |
| 2 | Abrupt cessation of tobacco use, or reduction in the amount of tobacco used, followed within 24 hours |
| 3 | Abrupt cessation of caffeine use followed within 24 hours by |
| 4 | during caffeine use |
| 5 | shortly after caffeine use |
| 6 | reduction in the amount of caffeine used, followed within 24 hours by |
| 7 | Withdrawal manifestations developing within several hours to a few days after the cessation of alcohol use |
| 8 | Withdrawal manifestations developing within several hours to a few days after reduction in alcohol use |
| 9 | behavioural or psychological changes developing during alcohol use |
| 10 | behavioural or psychological changes developing shortly after, alcohol use |
| 11 | Withdrawal manifestations developing within several hours to a few days after the cessation of cannabis use |
| 12 | Withdrawal manifestations developing within several hours to a few days after reduction in cannabis use |
| 13 | developing within 2 hours of cannabis use |
| 14 | behavioural or psychological changes developing within approximately 1 week after cessation of cannabis use that has been heavy and prolonged (i.e., usually daily or almost daily use over a period of at least a few months) |
| 15 | Clinically significant problematic behavioral changes that developed during, or shortly after, phencyclidine use |
| 16 | Intoxication symptoms developed within 1 hour, two (or more). Note: When the drug is smoked, "snorted," or used intravenously, the onset may be particularly rapid |
| 17 | Clinically significant problematic behavioral or psychological changes that developed during hallucinogen use |
| 18 | Clinically significant problematic behavioral or psychological changes that developed shortly after, hallucinogen use |
| 19 | Following cessation of use of a hallucinogen |
| 20 | Clinically significant problematic behavioral or psychological changes that developed during exposure to inhalants |
| 21 | Clinically significant problematic behavioral or psychological changes that developed shortly after exposure to inhalants |
| 22 | developing during inhalant use or exposure |
| 23 | developing shortly after inhalant use or exposure |
| 25 | problematic behavioral or psychological changes that developed during opioid use. |
| 26 | problematic behavioral or psychological changes that developed shortly after, opioid use. |
| 27 | problematic behavioral or psychological changes that developed during sedative, hypnotic, or anxiolytic use |
| 28 | problematic behavioral or psychological changes that developed shortly after, sedative, hypnotic, or anxiolytic use |
| 29 | problematic behavioral or psychological changes that developed during stimulant use |
| 30 | problematic behavioral or psychological changes that developed shortly after, sedative, hypnotic, or anxiolytic use |
| 31 | problematic behavioral or psychological changes that developed during ingestion of (or exposure to) a substance that is not listed elsewhere or is unknown |
| 32 | problematic behavioral or psychological changes that developed shortly after, sedative, hypnotic, or anxiolytic ingestion of (or exposure to) a substance that is not listed elsewhere or is unknown |
| 33 | problematic behavioral or psychological changes developing within minutes to several days after cessation of (or reduction in) opioid use that has been heavy and prolonged (i.e., several weeks or longer) or administration of an opioid antagonist after a period of opioid use |
| 34 | symptoms developing within several hours to a few days after the cessation of (or reduction in) sedative, hypnotic, or anxiolytic use* |
| 35 | symptoms developing within a few hours to several days after the cessation of (or reduction in) prolonged amphetamine-type substance, cocaine, or other stimulant use |
| 36 | The substance involved cannot be classified under any of the other substance categories (alcohol, caffeine; cannabis; opioids; sedatives, hypnotics, or anxiolytics; stimulants; or tobacco) or is unknown |
| 37 | have a distinct quality of depressed mood characterized by bodily/mental states |
| 38 | during manic episodes |
| 39 | in bipolar I or bipolar II disorder |

| index | gender | |
|-------|---------------------|--|
| 1 | non-gender specific | |
| 2 | male | |
| 3 | female | |

| index | age group | |
|-------|--------------------------|--|
| 1 | all | |
| 2 | adults | |
| 3 | children | |
| 4 | children and adolescents | |

| index | neutral behaviour prefix | |
|-------|--------------------------|--|
| 1 | do you | |
| 2 | are you | |
| 3 | can you | |
| 4 | does your | |
| 5 | are your | |
| 6 | is your | |
| 7 | were there | |
| 8 | do others | |
| 9 | have you | |
| 10 | are there | |
| 11 | do | |
| 12 | is there | |
| 13 | | |

| index | dimensional prefix |
|-------|--------------------|
| 1 | How often |
| 2 | For how long |

| index | neutral behaviour suffix | |
|-------|--------------------------|--|
| 1 | well | |
| 2 | intently | |
| 3 | with ease | |
| 4 | easily | |
| 5 | for long | |
| 6 | promptly | |
| 7 | good | |